SCHEMBL4481124

SCHEMBL4481124

Cc1[nH]c(C)c(-c2c[nH]c(OCc3cccc(C(F)(F)F)c3)cc2=O)c(=O)c1Br

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.65
MAOB P27338 6/20 0.39
MAOA P21397 2/20 0.39
SLC26A3 P40879 1/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
SLC6A4 P31645 1/20 0.38
MMP1 P03956 1/20 0.38
MMP12 P39900 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
BRD4 O60885 1/20 0.38
NR4A2 P43354 1/20 0.38
PTPN1 P18031 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PLAT P00750 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493329 0.90 SLC2A1 (0.52) SLC2A1BRD4PTPN1PLAT
SCHEMBL4476162 0.89 SLC2A1 (0.51) SLC2A1MAOBMAOAHCAR2PTPN1
SCHEMBL4468891 0.89 SLC2A1 (0.51) SLC2A1MAOBMAOASLC26A3MMP1
SCHEMBL4478994 0.83 SLC2A1 (0.55) SLC2A1BRD4
SCHEMBL4490856 0.82 SLC2A1 (0.42) SLC2A1MAOBMAOATHRBBRD4
SCHEMBL4493607 0.82 SLC2A1 (0.43) SLC2A1SLC6A4MMP1
SCHEMBL4483843 0.82 SLC2A1 (0.43) SLC2A1MAOBMAOASLC6A4HCAR2
SCHEMBL4491067 0.81 SLC2A1 (0.41) SLC2A1
SCHEMBL4493394 0.79 SLC2A1 (0.52) SLC2A1MAOBBRD4MAPTHTT
SCHEMBL4481121 0.79 SLC2A1 (1.00) SLC2A1MAOBMAOASLC26A3THRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885MAOB 351/4885MAOA 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.